Sp647
IMPLICATIONS OF THE CHANGING EPIDEMIOLOGY OF COLORECTAL CANCER FOR CLINICAL RESEARCH AND CLINICAL PRACTICE
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
Increasing risk for early onset CRC under age 50 has been well established. More recent trends suggest that this risk is extending beyond age 50, potentially expanding the public health impact of the factors driving increased risk. This symposium will: 1) Review the changing epidemiology of colorectal cancer; 2) Review potential causes from epidemiologic and basic science perspectives; 3) Discuss implications of the changing epidemiology for basic/translational research, as well as clinical research and clinical practice.
Increasing risk for early onset CRC under age 50 has been well established. More recent trends suggest that this risk is extending beyond age 50, potentially expanding the public health impact of the factors driving increased risk. This symposium will: 1) Review the changing epidemiology of colorectal cancer; 2) Review potential causes from epidemiologic and basic science perspectives; 3) Discuss implications of the changing epidemiology for basic/translational research, as well as clinical research and clinical practice.
Presenter
University of California San Diego
Tracks
Related Products
PANEL DISCUSSION
Increasing risk for early onset CRC under age 50 has been well established. More recent trends suggest that this risk is extending beyond age 50, potentially expanding the public health impact of the factors driving increased risk…
AGA 45 Is the New 50 and 50 the New 55: Epidemiology and Causes of the Shift in Colorectal Cancer Risk
Increasing risk for early onset CRC under age 50 has been well established. More recent trends suggest that this risk is extending beyond age 50, potentially expanding the public health impact of the factors driving increased risk…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
